Date: 2014-10-02
Type of information: R&D agreement
Compound: Mcl-1-inhibitory BH3-mimetics
Company: Servier (France) Walter and Eliza Hall Institute (Australia)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: * On October 2, 2014, Servier has established a collaborative partnership with the Walter and Eliza Hall Institute to facilitate the development of new agents that could be effective in treating several types of cancer, particularly blood cancers. A research team at the Walter and Eliza Hall Institute, led by Associate Professor Guillaume Lessene, will test in preclinical models how cancer cells respond to treatment with the Mcl-1-inhibitory BH3-mimetics discovered by the Servier - Vernalis collaboration. The results will indicate whether this new class of research compounds could be useful in the future for treating people with cancer, and which types of cancer the compounds would be most effective against. Mcl-1 is part of a closely related group of proteins known as the ‘Bcl-2 family’, which also includes proteins called Bcl-2 and Bcl-xL. Like Mcl-1, Bcl-2 and Bcl-xL are also important in extending the lifespan of certain types of cancer cells.
Financial terms:
Latest news:
